160 related articles for article (PubMed ID: 34863189)
1. Optimal authoritative risk assessment score of Cancer-associated venous thromboembolism for hospitalized medical patients with lung Cancer.
Xiong W; Zhao Y; Du H; Wang Y; Xu M; Guo X
Thromb J; 2021 Dec; 19(1):95. PubMed ID: 34863189
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients.
Rupa-Matysek J; Lembicz M; Rogowska EK; Gil L; Komarnicki M; Batura-Gabryel H
Med Oncol; 2018 Apr; 35(5):63. PubMed ID: 29616356
[TBL] [Abstract][Full Text] [Related]
3. Comparison among three predictive models for cancer-associated thromboembolism in a hispanic population.
Ramos-Esquivel A; Marenco-Flores A; Hernández-Romero G; Céspedes-Calvo A; Mora-Hidalgo R
J Thromb Thrombolysis; 2023 Oct; 56(3):433-438. PubMed ID: 37407771
[TBL] [Abstract][Full Text] [Related]
4. Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients.
Di Nisio M; van Es N; Rotunno L; Anzoletti N; Falcone L; De Tursi M; Natoli C; Tinari N; Cavallo I; Valeriani E; Candeloro M; Guglielmi MD; Rutjes AWS; Porreca E
J Thromb Thrombolysis; 2019 Jul; 48(1):125-133. PubMed ID: 30919253
[TBL] [Abstract][Full Text] [Related]
5. COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study.
Abdel-Razeq H; Sharaf B; Al-Jaghbeer MJ; Abu-Fares H; Bater R; Shaer MA; Abu-Jaish H; Laban DA; Salamah O; Tamimi F; Ashouri K; Salameh T; Zughul R; Alhalaseh Y
J Thromb Thrombolysis; 2023 Oct; 56(3):447-453. PubMed ID: 37430158
[TBL] [Abstract][Full Text] [Related]
6. Estimating Venous Thromboembolism Risk in Metastatic Colorectal Cancer Inpatients: Validation of Existing Risk Scores and Development of New Risk Scores.
Qin L; Liang Z; Xie J; Li X
Clin Appl Thromb Hemost; 2023; 29():10760296231196859. PubMed ID: 37691565
[TBL] [Abstract][Full Text] [Related]
7. Overview of risk assessment models for venous thromboembolism in ambulatory patients with cancer.
Gerotziafas GT; Mahé I; Lefkou E; AboElnazar E; Abdel-Razeq H; Taher A; Antic D; Elalamy I; Syrigos K; Van Dreden P
Thromb Res; 2020 Jul; 191 Suppl 1():S50-S57. PubMed ID: 32736779
[TBL] [Abstract][Full Text] [Related]
8. Models for predicting venous thromboembolism in ambulatory patients with lung cancer: A systematic review and meta-analysis.
Yan AR; Samarawickrema I; Naunton M; Peterson GM; Yip D; Newman P; Mortazavi R
Thromb Res; 2024 Feb; 234():120-133. PubMed ID: 38215613
[TBL] [Abstract][Full Text] [Related]
9. Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study.
Cella CA; Di Minno G; Carlomagno C; Arcopinto M; Cerbone AM; Matano E; Tufano A; Lordick F; De Simone B; Muehlberg KS; Bruzzese D; Attademo L; Arturo C; Sodano M; Moretto R; La Fata E; De Placido S
Oncologist; 2017 May; 22(5):601-608. PubMed ID: 28424324
[TBL] [Abstract][Full Text] [Related]
10. Validation of the ONKOTEV Risk Prediction Model for Venous Thromboembolism in Outpatients With Cancer.
Cella CA; Knoedler M; Hall M; Arcopinto M; Bagnardi V; Gervaso L; Pellicori S; Spada F; Zampino MG; Ravenda PS; Frassoni S; Passaro A; Milano M; Laffi A; Fazio N; Lordick F
JAMA Netw Open; 2023 Feb; 6(2):e230010. PubMed ID: 36795409
[TBL] [Abstract][Full Text] [Related]
11. [Risk prediction of venous thromboembolism in non-small cell lung cancer patients based on COMPASS-CAT risk assessment model].
Wang YF; Ma F; Liu BL; Yang K; Li JL; Yu L
Zhonghua Zhong Liu Za Zhi; 2020 Apr; 42(4):340-345. PubMed ID: 32375452
[No Abstract] [Full Text] [Related]
12. Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer.
Guman NAM; van Geffen RJ; Mulder FI; van Haaps TF; Hovsepjan V; Labots M; Cirkel GA; Y F L de Vos F; Ten Tije AJ; Beerepoot LV; Tjan-Heijnen VCG; van Laarhoven HWM; Hamberg P; Vulink AJE; Los M; Zwinderman AH; Ferwerda B; Lolkema MPJK; Steeghs N; Büller HR; Kamphuisen PW; van Es N
J Thromb Haemost; 2021 Dec; 19(12):2974-2983. PubMed ID: 34409743
[TBL] [Abstract][Full Text] [Related]
13. ONKOTEV Score as a Predictive Tool for Thromboembolic Events in Pancreatic Cancer-A Retrospective Analysis.
Godinho J; Casa-Nova M; Moreira-Pinto J; Simões P; Paralta Branco F; Leal-Costa L; Faria A; Lopes F; Teixeira JA; Passos-Coelho JL
Oncologist; 2020 Feb; 25(2):e284-e290. PubMed ID: 32043787
[TBL] [Abstract][Full Text] [Related]
14. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study.
Kruger S; Haas M; Burkl C; Goehring P; Kleespies A; Roeder F; Gallmeier E; Ormanns S; Westphalen CB; Heinemann V; Rank A; Boeck S
Thromb Res; 2017 Sep; 157():9-15. PubMed ID: 28675831
[TBL] [Abstract][Full Text] [Related]
15. A Predictive Score for Thrombosis Associated with Breast, Colorectal, Lung, or Ovarian Cancer: The Prospective COMPASS-Cancer-Associated Thrombosis Study.
Gerotziafas GT; Taher A; Abdel-Razeq H; AboElnazar E; Spyropoulos AC; El Shemmari S; Larsen AK; Elalamy I;
Oncologist; 2017 Oct; 22(10):1222-1231. PubMed ID: 28550032
[TBL] [Abstract][Full Text] [Related]
16. A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients.
Gomez-Rosas P; Giaccherini C; Russo L; Verzeroli C; Gamba S; Tartari CJ; Bolognini S; Ticozzi C; Schieppati F; Barcella L; Sarmiento R; Masci G; Tondini C; Petrelli F; Giuliani F; D'Alessio A; Minelli M; De Braud F; Santoro A; Labianca R; Gasparini G; Marchetti M; Falanga A; On Behalf Of The Hypercan Investigators
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760562
[TBL] [Abstract][Full Text] [Related]
17. A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer.
Li S; Gao P; Qiu J; He X; Mao Y
J Thromb Thrombolysis; 2021 Oct; 52(3):898-903. PubMed ID: 33599857
[TBL] [Abstract][Full Text] [Related]
18. Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an ambulatory cancer centre.
Pelletier R
J Oncol Pharm Pract; 2021 Jun; 27(4):911-918. PubMed ID: 33757321
[TBL] [Abstract][Full Text] [Related]
19. Comparison between the Khorana prediction score and Caprini risk assessment models for assessing the risk of venous thromboembolism in hospitalized patients with cancer: a retrospective case control study.
Hu Y; Li X; Zhou H; Lin P; Zhang J; Huang D; Qi M; Tang Y; Yi Q; Liang Z; Wang M
Interact Cardiovasc Thorac Surg; 2020 Oct; 31(4):454-460. PubMed ID: 32910201
[TBL] [Abstract][Full Text] [Related]
20. Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data.
Tsubata Y; Kawakado K; Hamai K; Furuya N; Yokoyama T; Saito R; Nakamura A; Masuda T; Hamaguchi M; Kuyama S; Honda R; Senoo T; Nakanishi M; Hotta T; Yamasaki M; Ishikawa N; Fujitaka K; Kubota T; Kobayashi K; Isobe T
Int J Clin Oncol; 2023 Jan; 28(1):69-78. PubMed ID: 36357710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
